| Active substance |
Budesonide, Formoterol |
| Also known as |
Budesonida, Budesonidum |
| Blood pressure |
Typically does not affect blood pressure |
| Chemical name |
(RS)-11ОІ,16О±,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde |
| Dosage (medical) |
Varies based on treatment type, commonly inhaled 100-800 mcg daily in divided doses for asthma |
| Dosage (sports) |
Not typically used for performance enhancement |
| Effects |
Reduces inflammation and immune response |
| Formula |
C25H34O6 |
| Half-life |
2 to 3.6 hours |
| Hepatotoxicity |
Low |
| Lab Test |
Specific tests for monitoring budesonide levels are not commonly used in clinical practice |
| Main action |
Anti-inflammatory |
| Side effects |
Oral thrush, voice changes, cough, sore throat, and, with long-term use, adrenal suppression |
| Storage conditions |
Store at 20В°C to 25В°C (68В°F to 77В°F) |
| Substance class |
Corticosteroid |
| Trade name |
Pulmicort, Rhinocort, others |
| Use in sports |
Not commonly used for enhancing athletic performance, but may be used therapeutically for asthma |
| Water Retention |
Minimal |
| Manufacturer |
Cadila Pharmaceuticals Ltd. |
| Packing |
1 Inhaler/pack |
